State of New Jersey Common Pension Fund D Sells 9,814 Shares of TransMedics Group, Inc. $TMDX

State of New Jersey Common Pension Fund D cut its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 39.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,270 shares of the company’s stock after selling 9,814 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in TransMedics Group were worth $2,046,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. AlphaQuest LLC increased its position in shares of TransMedics Group by 51.4% during the 2nd quarter. AlphaQuest LLC now owns 1,950 shares of the company’s stock valued at $261,000 after purchasing an additional 662 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new stake in TransMedics Group during the 2nd quarter valued at about $499,000. Phoenix Financial Ltd. purchased a new stake in TransMedics Group during the 2nd quarter valued at about $272,000. Values First Advisors Inc. boosted its holdings in TransMedics Group by 8.7% during the 2nd quarter. Values First Advisors Inc. now owns 6,126 shares of the company’s stock valued at $821,000 after acquiring an additional 489 shares during the period. Finally, New York State Teachers Retirement System boosted its holdings in TransMedics Group by 25.9% during the 2nd quarter. New York State Teachers Retirement System now owns 27,638 shares of the company’s stock valued at $3,704,000 after acquiring an additional 5,689 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Trading Up 3.6%

NASDAQ TMDX opened at $134.32 on Thursday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $145.50. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The stock has a 50 day simple moving average of $116.47 and a two-hundred day simple moving average of $116.99. The stock has a market cap of $4.58 billion, a P/E ratio of 69.60 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.29. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.During the same period in the previous year, the company posted $0.12 earnings per share. The company’s revenue for the quarter was up 32.2% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on TMDX shares. Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Jefferies Financial Group started coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 target price for the company. Morgan Stanley increased their target price on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Finally, Needham & Company LLC upgraded TransMedics Group from a “hold” rating to a “buy” rating and set a $148.00 target price for the company in a report on Thursday, October 23rd. Eight equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average target price of $130.73.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.